Financial Data and Key Metrics Changes - Consolidated revenues for Q1 FY '24 were INR 6,738 crores (USD 821 million), representing a year-on-year growth of 29% and a sequential growth of 7% [5] - Adjusted for brand divestment income, underlying growth was 35% year-on-year and 12% sequentially [5] - Reported EPS for the quarter was INR 84.22, with operating working capital increasing by INR 710 crores (USD 87 million) [7] - EBITDA for the quarter was INR 2,137 crores (USD 260 million), with an EBITDA margin of 31.7% [128] Business Line Data and Key Metrics Changes - North America generic business recorded sales of USD 389 million, a strong growth of 69% year-on-year and a 25% sequential increase [118] - India business sales were INR 1,140 crores, with a growth of 14% excluding revenue from brand divestment [119] - Emerging market business recorded sales of INR 1,155 crores, with a year-on-year growth of 28% and a sequential increase of 4% [134] - The PCI business saw sales of USD 82 million, with a year-over-year decline of 11% and a sequential decline of 14% [13] Market Data and Key Metrics Changes - The Euro business recorded sales of EUR 57 million with year-on-year growth of 13% [12] - The Russia business grew by 77% year-on-year and 7% sequentially in constant currency, driven by seasonal demand [134] - The company expects sales to improve in the coming quarters due to increasing volume pickup and new product launches [134] Company Strategy and Development Direction - The company is focused on building a healthy pipeline of new products, including biosimilars, and has launched eight new products during the quarter [6][12] - The company aims to ramp up growth in the India business by scaling up recently acquired brands and improving field productivity [13] - The company is maintaining a disciplined approach to cash management and acquisitions, with a focus on strategic fit for any potential acquisitions [14][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum and strengthening core business through productivity improvements and market share gains [14][115] - The management noted that price erosion has reduced and is expected to continue, contributing positively to future performance [17][19] - The company anticipates significant growth in China starting from FY '25, with ongoing investments in R&D and product development [50][68] Other Important Information - The company has entered into a collaboration with the Bill and Melinda Gates Foundation to develop injectable contraceptive drugs for low and middle-income countries [132] - The company has a net surplus cash of INR 4,985 crores (USD 608 million) as of June 30, 2023, providing financial flexibility for future growth [129] Q&A Session Summary Question: What are the primary drivers of revenue growth in the US? - Management indicated that the growth was driven by a combination of volume-based growth, agreements with customers, and a reduction in price erosion [123][138] Question: How sustainable is the growth seen in Russia? - Management noted that while the growth momentum is expected to continue, the Russian market is volatile and may fluctuate [146] Question: What is the outlook for EBITDA margins excluding Revlimid? - Management expects EBITDA margins to remain above the threshold in the coming quarters, supported by volume agreements [143] Question: How does the company plan to achieve a more diversified geographic mix? - Management stated that innovation and new product launches will be key to achieving a more balanced revenue mix across geographies [62][64] Question: What are the company's priorities for capital allocation? - Management indicated that acquisitions in India and emerging markets would rank higher, with a focus on strategic fit and reasonable pricing [65][66]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F |  | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | |  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the Fiscal Year Ended March 31, 2023 | | | OR | |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | |  | SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

[Company Information and Regulatory Context](index=1&type=section&id=Company%20Information%20and%20Regulatory%20Context) Dr. Reddy's Laboratories Ltd. provides regulatory intimation regarding upcoming analyst and institutional investor meetings [Purpose of Intimation](index=1&type=section&id=Sub%3A%20Intimation%20under%20Regulation%2030%20of%20the%20Securities%20and%20Exchange%20Board%20of%20India%20%28Listing%20Obligations%20and%20Disclosure%20Requirements%29%20Regulations%2C%202015%20-%20Schedule%20of%20Analyst%20%2F%20Institutional%20Investor%20Meetings) Dr. Reddy's Laboratories Ltd. informs stock exchanges of upcoming analyst and investor meetings under SEBI Regulation 30 - Dr. Reddy's Laboratories Ltd. provides intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015[1](index=1&type=chunk) - The intimation concerns the schedule of upcoming Analyst / Institutional Investor Meetings[1](index=1&type=chunk) [Schedule of Analyst / Institutional Investor Meetings](index=1&type=section&id=Schedule%20of%20Analyst%20%2F%20Institutional%20Investor%20Meetings) The company's upcoming analyst and institutional investor meetings are detailed with dates, organizers, and formats [Meeting Details](index=1&type=section&id=Meeting%20details%20table) Management will attend four investor events from June 13-20, 2023, including a global healthcare conference and group meetings Meeting details table | Date | Organized by | Meeting details | Location | Timing | |---|---|---|---|---| | 13-Jun-23 | Goldman Sachs | 44th Annual Global Healthcare Conference | California, US | 08:40 to 17:15 hrs PDT (from 9:10 pm IST) | | 15-Jun-23 | BofA Securities | Investor group meeting | Virtual | 16:00 to 17:00 hrs IST | | 19-Jun-23 | Kotak Securities | Investor group meeting | Hyderabad | 10:00 to 11:00 hrs IST 14:00 to 17:00 hrs IST | | 20-Jun-23 | JM Financial Institutional Securities | Investor group meeting | Hyderabad | 10:00 to 11:30 hrs IST | [Important Notes and Formalities](index=1&type=section&id=Important%20Notes%20and%20Formalities) Disclaimers on meeting schedule changes and formal signatory and distribution details for the intimation are provided [Disclaimer on Schedule Changes](index=1&type=section&id=Please%20note%20that%20the%20schedules%20of%20the%20aforesaid%20meetings%20are%20subject%20to%20change%20due%20to%20any%20exigencies%20on%20the%20part%20of%20Investors%20%2F%20Company.) Meeting schedules are provisional and subject to change due to exigencies from investors or the company - Meeting schedules are subject to change due to exigencies on the part of Investors / Company[1](index=1&type=chunk) [Signatory and Distribution](index=2&type=section&id=Yours%20faithfully%2C%20For%20Dr.%20Reddy%27s%20Laboratories%20Limited%20%2Fs%2F%20K%20Randhir%20Singh%20K%20Randhir%20Singh%20Company%20Secretary%2C%20Compliance%20Of%20icer%20and%20Head%20CSR%20CC%3A-%20New%20York%20Stock%20Exchange%20Inc.%28Stock%20Code%20%3ARDY%29%20NSE%20IFSC%20Ltd) The intimation was formally submitted by K Randhir Singh, Company Secretary, and distributed to major stock exchanges - The intimation was signed by K Randhir Singh, Company Secretary, Compliance Officer, and Head CSR[2](index=2&type=chunk) - Copies were sent to New York Stock Exchange Inc. (Stock Code: RDY) and NSE IFSC Ltd, in addition to the primary recipients[2](index=2&type=chunk)

Financial Data and Key Metrics Changes - Revenue for FY 2023 stood at INR 4,588 crores (USD 2.99 billion), growing by 15% year-on-year, driven by new product launches and partially offset by price erosion [10] - Gross margin for FY 2023 was 56.7%, an increase of 360 bps over FY 2022, attributed to new product sales with higher gross margins and favorable foreign exchange [11] - EBITDA for FY 2023 was INR 7,308 crores (USD 889 million), with an EBITDA margin of 25.9% [12] - Profit after tax for FY 2023 was INR 4,507 crores (USD 548 million), with reported EPS of INR 27.85 [21] Business Line Data and Key Metrics Changes - North America Generics business recorded sales of USD 1.68 billion for FY 2023, growing by 26% year-on-year, driven by new product launches [31] - Europe business sales for FY 2023 were USD 210 million, growing by 9%, supported by base business volume and new product launches [32] - Emerging markets recorded sales of USD 1,114 million, with a year-over-year decline of 7% but grew 13% when adjusted for COVID-related products [33] - India business sales for Q4 were INR 1,293 crores, with a year-over-year growth of 32% [35] Market Data and Key Metrics Changes - North America generics and branded markets crossed the $1 billion mark for the second consecutive year [26] - The Russia business declined by 9% in constant currency for FY 2023, attributed to the divestment of noncore brands [35] - The company expects to see growth in the ROW markets, aiming to return to historical growth rates of 20% to 25% [61] Company Strategy and Development Direction - The company is focused on strengthening its core businesses while investing in future growth opportunities, including biosimilars and digitalization [25][39] - Strategic acquisitions and collaborations are being pursued to enhance product offerings and market presence [27][53] - The company aims to maintain a disciplined approach to cash management and acquisitions, focusing on complementary products rather than transformational deals [121][122] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth across all markets, including the U.S. [81] - The company anticipates continued growth driven by new product launches and strategic investments in R&D [51][88] - Management acknowledged the challenges of price erosion in the U.S. market but noted a better product mix in the recent quarter [56] Other Important Information - The company generated a strong free cash flow leading to a net cash surplus of INR 5,046 crores (USD 640 million) as of March 31, 2023 [23] - R&D spend for FY 2023 was INR 1,938 crores (USD 238 million), representing 7.9% of sales [12] Q&A Session Summary Question: Details on recent deals and responsibilities - Management discussed strategic dialogues with the innovation industry in China to bring affordable products to India [44] Question: Sequential growth in the U.S. business - Management indicated consistent growth in the U.S. market driven by organic activities and new product launches [46][49] Question: Launch momentum in the U.S. market - Management highlighted expectations for 25 to 30 meaningful product launches with less competition in FY 2024 [51] Question: Growth expectations in ROW markets - Management confirmed aims for traditional growth rates in ROW markets, focusing on product development and hospital business [61] Question: Impact of divestment income in India - Management quantified divestment income at INR 264 crores and indicated ongoing efforts to enhance product offerings [62] Question: Price erosion in existing products - Management noted a better product mix in the recent quarter, with less price erosion compared to previous quarters [56] Question: Future R&D and SG&A cost expectations - Management expects R&D spending to remain between 8% to 9% of sales, with a focus on biologics and products with less competition [59] Question: Growth in the U.S. generics market - Management expressed confidence in achieving growth in the U.S. market, supported by new product launches [88] Question: M&A strategy and cash utilization - Management confirmed a focus on bolt-on acquisitions and strategic collaborations rather than transformational deals [121][122]

Ladies and gentlemen, good day, and welcome to Dr. Reddy's Laboratories Limited Q3 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. [Operator Instructions] Please note that this conference is being recorded. Richa Periwal All the discussion and analysis of this call will be based on the IFRS consolidated financial statements. To discuss the business performance an ...

Dr.Reddy's Financial Results Q3 FY23 Jan 25th, 2023 1 | January 25 | Q3 FY23 Press Meet th, 2023 | As per consolidated financial statements under IFRS Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical ...

Call Start: 09:00 January 1, 0000 10:05 AM ET Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2023 Earnings Conference Call October 28, 2022 09:00 ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Tarang Agarwal - Old Bridge Capital Prakash Agarwal - Axis Capital Kunal Dhamesha - Macquarie Capital Damayanti Kerai - HSBC Surya Patra - Philip Capital Sameer Baisiwala ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______ DR. REDDY'S LABORATORIES LIMITED (Translation of registrant's name into English) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40 ...

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q1 2023 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Saion Mukherjee - Nomura Anubhav Aggarwal - Credit Suisse Damayanti Kerai - HSBC Prakash Agarwal - Axis Capital Neha Manpuria - Bank of America Sameer Baisiwala - Morgan Stanley Surya Patra - Philip Capital Tarang A ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June, 2022 Commission File Number 1-15182 DR. REDDY'S LABORATORIES LIMITED (Translation of registrant's name into English) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under ...